[Chemotherapy of soft tissue sarcomas]

Area of Science:

• Medical Oncology
• Pharmacology
• Sarcoma Research

Context:

• Metastatic soft tissue sarcomas (STS) represent a challenging group of rare cancers with limited treatment options.
• Previous chemotherapy had not been administered to the 62 patients included in this study.
• The study focuses on evaluating the efficacy of Cyvadic in treatment-naïve patients with diverse STS histological subtypes.

Purpose:

• To assess the efficacy and response rates of Cyvadic in patients with metastatic soft tissue sarcomas.
• To determine the duration of response and survival outcomes for patients treated with Cyvadic.
• To evaluate the effectiveness of salvage chemotherapy (ifosfamide plus cisplatin) in patients resistant to Cyvadic.

Summary:

• Treatment with Cyvadic resulted in a 10% complete remission (CR) rate and a 20% overall CR plus partial remission (PR) rate in 62 treatment-naïve metastatic STS patients.
• The median survival time for responders was 28 months, compared to 14 months for non-responders.
• Salvage chemotherapy with ifosfamide plus cisplatin achieved a 50% CR + PR rate in patients who developed resistance to Cyvadic.

Impact:

• This study provides valuable data on Cyvadic's efficacy in metastatic STS, establishing a benchmark for first-line treatment.
• The findings highlight the potential of ifosfamide plus cisplatin as an effective salvage regimen for Cyvadic-refractory STS.
• Results contribute to understanding treatment sequencing and optimizing therapeutic strategies for advanced soft tissue sarcomas.